Pfizer Pain Pipeline Gains Adolor’s Delta Opioid Agonist Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
$260 million-plus licensing agreement includes two early-stage compounds for inflammatory, acute and neuropathic pain.
You may also be interested in...
Adolor Abandons Entereg Chronic OBD Indication, Faces Other Setbacks
Adolor is abandoning development of Entereg (alvimopan) for chronic opioid bowel dysfunction just three months after its post-operative ileus partner, GlaxoSmithKline, returned rights for chronic indications
Adolor Abandons Entereg Chronic OBD Indication, Faces Other Setbacks
Adolor is abandoning development of Entereg (alvimopan) for chronic opioid bowel dysfunction just three months after its post-operative ileus partner, GlaxoSmithKline, returned rights for chronic indications
Adolor Faces R&D Setbacks, One With Entereg
Adolor discontinues development of alvimopan to treat chronic opioid bowel dysfunction after unsuccessful partnering discussions; it will proceed with the preclinical compound ADL7445.